{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:09:09Z","timestamp":1778566149833,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332024182"],"award-info":[{"award-number":["3332024182"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017287","name":"Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutes of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC3601803"],"award-info":[{"award-number":["2022YFC3601803"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030097"],"award-info":[{"award-number":["82030097"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2022-RC310-04"],"award-info":[{"award-number":["2022-RC310-04"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102643","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:42:41Z","timestamp":1755240161000},"page":"102643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["B cell\u2013targeted therapies in autoimmune skin disease: current advances and challenges"],"prefix":"10.1016","volume":"96","author":[{"given":"Zhi","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102643_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103841","article-title":"Genetic and immune dysregulation in vitiligo: insights into autoimmune mechanisms and disease pathogenesis","volume":"24","author":"Upadhya","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102643_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.tips.2024.10.016","article-title":"Advances in cell therapy: progress and challenges in hematological and solid tumors","volume":"45","author":"D'Avanzo","year":"2024","journal-title":"Trends Pharm Sci"},{"key":"10.1016\/j.coi.2025.102643_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.coi.2025.102643_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.coi.2019.09.004","article-title":"B cell targeted therapies in autoimmune disease","volume":"61","author":"Barnas","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102643_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/j.1460-2075.1988.tb02867.x","article-title":"Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains","volume":"7","author":"Einfeld","year":"1988","journal-title":"Embo J"},{"key":"10.1016\/j.coi.2025.102643_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102643_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.smim.2007.12.006","article-title":"Phenotypic and functional heterogeneity of human memory B cells","volume":"20","author":"Sanz","year":"2008","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib11","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2025.102643_sbref13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102643_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF AND APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib15","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102643_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103329","article-title":"The emerging role of BLyS\/APRIL in autoimmune diseases: biological characteristics, functions, and therapeutic potential","volume":"149","author":"Hu","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102643_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102643_bib18","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.4049\/jimmunol.1800393","article-title":"Integrated B cell, toll-like, and BAFF receptor signals promote autoantibody production by transitional B cells","volume":"201","author":"Du","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251910845","article-title":"B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus","volume":"25","author":"Martin","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2025.102643_bib20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102643_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102643_sbref22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_bib23","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102643_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2025.102643_bib25","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/ard-2023-224152","article-title":"Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus","volume":"82","author":"Alexander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_bib26","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102643_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_bib28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00498","article-title":"Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab","volume":"7","author":"Hassan","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.coi.2025.102643_bib30","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102643_sbref31","article-title":"Tissue-resident immune cells: from defining characteristics to roles in diseases","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2025.102643_bib32","first-page":"311","article-title":"Age-associated B cells (ABCs) in the prognosis, diagnosis and therapy of systemic lupus erythematosus (SLE)","volume":"31","author":"Sachinidis","year":"2020","journal-title":"Mediterr J Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2021-eular.2366","article-title":"POS0003\u2005Rituximab therapy in systemic lupus erythematosus \u2013 transient effects on age associated B-cells","volume":"80","author":"Faustini","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_sbref34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102643_sbref35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coi.2025.102643_bib36","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","article-title":"B cells in systemic sclerosis: a possible target for therapy","volume":"10","author":"Bosello","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102643_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","article-title":"Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes","volume":"54","author":"Matsushita","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102643_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","article-title":"Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib39","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib40","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102643_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2025.102643_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1454913","article-title":"CD19: a promising target for systemic sclerosis","volume":"15","author":"Komura","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102643_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2025.102643_bib45","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S2665-9913(24)00311-4","article-title":"CD19-targeting CAR-T cell treatment in patients with diffuse systemic sclerosis","volume":"7","author":"Avouac","year":"2024","journal-title":"Lancet Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib46","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.coi.2025.102643_bib47","doi-asserted-by":"crossref","first-page":"26552","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.coi.2025.102643_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102643_bib49","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.coi.2025.102643_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102643_bib51","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-024-03153-6","article-title":"Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis","volume":"19","author":"Shi","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.coi.2025.102643_bib52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2022.08.2209","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-positive dermatomyositis","volume":"163","author":"Holzer","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.coi.2025.102643_bib53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2024.04.060","article-title":"Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: a retrospective observational study","volume":"91","author":"Liu","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib54","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-cell-engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102643_bib55","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102643_sbref56","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamadermatol.2023.5679","article-title":"Sustained remission without corticosteroids among patients with pemphigus who had rituximab as first-line therapy: follow-up of the Ritux 3 trial","volume":"160","author":"Tedbirt","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib57","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102643_bib58","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/ced.15213","article-title":"Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus","volume":"47","author":"Singh","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib59","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14349","article-title":"A randomized study comparing full dose and half dose of rituximab in relapsing pemphigus patients","volume":"33","author":"Saleh","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coi.2025.102643_bib61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib62","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102643_sbref63","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166357","article-title":"Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters","volume":"133","author":"Han","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102643_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jid.2019.07.717","article-title":"Autoreactive B cell differentiation in diffuse ectopic lymphoid-like structures of inflamed pemphigus lesions","volume":"140","author":"Zhou","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102643_bib65","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/rheumatology\/keab827","article-title":"Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?","volume":"61","author":"Reddy","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102643_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3961","article-title":"Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia","volume":"13","author":"Crickx","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102643_bib67","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2007-11-123844","article-title":"The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells","volume":"111","author":"Mamani-Matsuda","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102643_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2025.102643_bib69","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:15:11Z","timestamp":1778562911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":69,"alternative-id":["S0952791525001190"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102643","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B cell\u2013targeted therapies in autoimmune skin disease: current advances and challenges","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102643"}}